Acadia Pharmaceuticals (ACAD) Non-Current Assets (2010 - 2026)

Acadia Pharmaceuticals' Non-Current Assets history runs 17 years deep, the most recent figure standing at $509.2 million for Q1 2026.

• In Q1 2026, Non-Current Assets rose 94.79% year-over-year to $509.2 million; the TTM figure through Mar 2026 stood at $1.5 billion (up 73.03% YoY), while the FY2025 annual figure was $502.1 million, up 101.29% from the prior year.
• Non-Current Assets for Q1 2026 stood at $509.2 million, up from $502.1 million in the prior quarter.
• The five-year high for Non-Current Assets was $509.2 million in Q1 2026, with the low at $79.9 million in Q4 2022.
• The 5-year median for Non-Current Assets is $179.8 million (2024), against an average of $205.1 million.
• The sharpest annual moves came in 2022 and 2025: Non-Current Assets retreated 2.95% in 2022, then soared 101.29% in 2025.
• Acadia Pharmaceuticals' Non-Current Assets stood at $79.9 million in 2022, then jumped by 66.3% to $132.8 million in 2023, then soared by 87.79% to $249.4 million in 2024, then jumped by 101.29% to $502.1 million in 2025, then rose by 1.42% to $509.2 million in 2026.
• Business Quant data shows ACAD's Non-Current Assets at $509.2 million in Q1 2026, $502.1 million in Q4 2025, and $254.3 million in Q3 2025.